November 21st 2024
The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.
October 14th 2024
For the pharmaceutical industry, drug formulation is a cornerstone, crucial for converting bioactive molecules into effective, stable, and patient-friendly medications.
September 27th 2024
Solving the challenge of better-stabilized temperature-sensitive biomolecules hinges on innovative formulation strategies.
August 11th 2024
Employing novel technologies and more patient-centric approaches can help to reduce the potential of formulation failure.
June 12th 2024
CordenPharma has partnered with Spain-based Certest to develop ionizable lipids for LNP formulations.
Risks and Rewards of Investing in RNA-based Genetic Medicine Manufacturing
Collaboration is a key component to achieving long-term success with genetic medicines.
Trends in Formulation for Highly Potent Drugs
When considering manufacturing and the growth of drug formulation, it is evident that there has been change and many new advancements introduced to make processes more efficient.
CPHI Annual Report Predicts AI Transformation of All Drug Development Processes by 2026
According to a press release, the implications go to the extent that within the next 10 years, more than 50% of approved drugs will involve AI in their development and/or manufacturing.
Optibrium Acquires BioPharmics
Optibrium announced on Aug. 31, 2023 the acquisition of BioPharmics to further expand the 3D drug design and modelling offering and to focus on research and development and application science.
Sparian Biosciences Awarded Five-Year NIH/NDA Grant for Development of SBS-518
SBS-518 is a first-in-class dual sigma receptor (SR) antagonist/dopamine transporter (DAT) inhibitor in development for the treatment of stimulant use disorder (StUD).
Exploring Drug Storage, Drug Dosage, and the Supply Chain with Ulrike Lemke (DCAT Week)
Dr. Ulrike Lemke, Head of Sterile Fill Finish at Recipharm, sat down with Grant Playter, associate editor, to discuss drug delivery forms.
New QSAR Model for Predicting Blood Brain Barrier Permeability
These models are useful in predicting whether an unknown substance of abuse can permeate the BBB to produce effects predicted by the Public Health Assessment via Structural Evaluation (PHASE) approach.
Catalent Licenses Bhami Research Laboratory Technology for Biologics Formulation Development
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
Influencing Change in Drug Delivery
Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.
Pharmacovigilance Risk Assessment Committee Meeting Highlights
The members reviewed the measures to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders.
FDA Publishes Draft Guidance on Statistical Approaches to Establishing Bioequivalence
The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.
Putting a Spotlight on Particle Engineering
Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.
The Next Generation of Male Contraceptives
One company reaches beyond traditionally-conceived male contraceptives with Vasalgel, a reversible hydrogel injectable.
Adopting Smart Development Strategies
External expertise is beneficial in helping companies select the right tools at the right stages of development to ensure success.
Reformulating Success
There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.
The Future of Drug Delivery for Biopharmaceuticals
Some of the greatest advancements in drug delivery are related to disposable delivery devices, vaccine adjuvants, and wearable pumps, according to Nicholas W. Warne of Pfizer.
Delivering a Difference in Formulation
It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.
Adapting to Solubility/Bioavailability Challenges
Industry is adapting to the increasing complexity and poor solubility and bioavailability of molecules in the pipeline.
Formulating Biologics: A Learning Curve
Biologics are forming a greater proportion of the development pipeline, but there are still some formulation difficulties to overcome to ensure clinical and commercial success.
Focusing on the Patient in Drug Development
Putting the patient at the forefront of drug development is essential, particularly to ensure medication compliance is optimized.
Formulating the Best Approach for Tablets
An early formulation strategy for tablets that is simple and scalable is recommended to ensure fewer downstream problems.
The Shape of Dosage Forms
Technological advances are helping shape the dosage forms of the future.
Successfully Accelerating Formulation Strategies
Developers need to consider key challenges when approaching accelerated formulation strategies to ensure success.
Predicting Toxicity in Drug Development
Toxicology studies are an important and required aspect of drug development that are performed to ensure that drugs are deemed safe prior to patient administration and use in clinical trials.
Tackling the Big Issue of Solubility
Poor solubility remains a big issue for drug development and, as such, is driving innovation in approaches and use of novel technologies to help overcome the associated challenges.
The Earlier the Better for Formulation Strategies
Investing in formulation strategies earlier on in development will maximize the chance of success.
Taking an Alternative Approach to Drug Delivery
Alternative drug delivery approaches are promising, but due to their complexity, they need to be sufficiently justified.
Crystec, Biosidus Collaborate on Enhanced Delivery and Performance of Biotherapeutics
Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.
Considering Bio/Pharma Reformulation Strategies
Reformulation strategies are useful tools for more than just stretching out the potential return on investment for a product.
Getting a Nose for Vaccines
The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.